Back

Evaluation of clinical need, effectiveness, and safety of the first myosin inhibitor mavacamten in real world patients

30 August 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Hypertrophic obstructive cardiomyopathy (HOCM): clearing the roadblock Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Leni Katharina Seuthe

Cologne University Hospital - Heart Center, Cologne (Germany)

8 More presentations in this session

Presentation thumbnail
Epidemiology and prognosis of obstructive and non-obstructive hypertrophic cardiomyopathy in Finland: a nationwide cohort study
Assistant Professor M. Laine (Helsinki, FI)
Abstract Slides Video
Presentation thumbnail
Non-invasive assessment of left ventricular hemodynamic forces in hypertrophic cardiomyopathy
Doctor G. Panichella (Florence, IT)
Abstract Slides Video
Presentation thumbnail
Functional capacity by cardiopulmonary exercise testing is not related to health status in obstructive hypertrophic cardiomyopathy
Doctor L. Bjerregaard (Aarhus N, DK)
Abstract Slides Video
Presentation thumbnail
Hemodynamic effects of right and biventricular pacing during exercise in hypertrophic obstructive cardiomyopathy
Doctor T. Ahmed (Oslo, NO)
Abstract Slides Video
Presentation thumbnail
Assessing the alignment of obstructive hypertrophic cardiomyopathy pharmacological treatments with ESC guidelines in Germany
Associate Professor F. Sedaghat-Hamedani (Heidelberg, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic obstructive cardiomyopathy (HOCM): clearing the roadblock

The Event

Event poster

ESC Congress 2024

30 August 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Hemodynamic and symptomatic response in real-world patients with hypertrophic obstructive cardiomyopathy and myosin inhibitor therapy
thumbnail
Congress Presentation
Mavacamten real-world experience: insights from the Dutch HCM Network.
thumbnail
Congress Presentation
Real-world insights into mavacamten use for obstructive hypertrophic cardiomyopathy: symptomatic improvement before gradient reduction?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources